Notice ID: 1a56369f68880f654c1ca5abea06d1ebPresolicitation
VOYAGER 1 AND 2 MAGNETOMETER SCIENCE DATA PRODUCTION
Archived on January 1, 2022. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 6:04 PM UTC−05:00
- Posted
- May 18, 2018
- Notice type
- Presolicitation
- NAICS
- NAICS 54171 Research and Development in the Physical, Engineering, and Life Sciences (reported as 541710)
Notice details
- Place of performance
- Vendor's Location, DAVIDSONVILLE, 21035
- PSC
- A: RESEARCH AND DEVELOPMENT
- Last updated
- Sep 25, 2026
Identifiers
- Solicitation number
- VOYAGER_PROJECT
- Notice ID
- 1a56369f68880f654c1ca5abea06d1eb
Description
NASA/Goddard Space Flight Center (GSFC) has a requirement for scientific research for the fully calibrated Voyager 1 and 2 magnetic field data that shall incorporate the spacecraft magroll maneuvers, instrument magcal results, and comparison of the inboard and outboard magnetometer measurements. Spacecraft induced data spikes and offsets shall be removed from the data set. The science research performed with the Voyager 1 and 2 magnetic field data shall demonstrate and validate that the measurements are consistent with the inner and outer heliosheath environment the spacecraft are currently traversing. Expert consultation shall include, but not limited to, expert advice on the proper processing of the voyager 1 and 2 magnetic field data during long durations of no spacecraft roll maneuvers. The NASA Voyager 1 and 2 spacecraft were launched in 1977 on a mission to explore the outer gas giant planets. After Voyager 2 passed by the Neptune system in 1989, the twin spacecraft were recommissioned to study the outer reaches of our heliosphere and the local interstellar medium, called the Voyager Interstellar Mission (VIM). Voyager 1 crossed the heliopause, the outer boundary of the heliosphere in 2012 entering into the local interstellar medium for the first time. Voyager 2 is expected to reach interstellar space in the next couple of years. Each Voyager spacecraft carries two fluxgate magnetometers on a 13 m boom to measure the ambient magnetic field vectors. Since the magnetometers were optimized for the large fields of the outer planets, calibrating the instruments for the very small outer heliospheric and interstellar fields is a very complex process. The calibration procedure, developed over the past two decades, relies on occasional spacecraft rolls and an internal electronic magcal process. In addition, the measurements obtained by the two magnetometers are compared, and spacecraft induced noises are eliminated. This contract is for the continued execution of this magnetometer calibration process for the next year, with an option for two additional years. NASA/GSFC intends to issue a sole-source Request for Proposal (RFP) to BURLAGA, LEONARD F. The data validation process for the magnetometers has been developed and is being executed by Dr. Leonard Burlaga. The estimated period of performance for this firm fixed price (FFP) contract will be for one year from date of award. Statutory authority for this procurement is 10 U.S.C. 2304(c)(1)--Only One Responsible Source. However, organizations who believe they can provide these services without any detrimental impact to the program schedules supported by this work should fully identify their interest and capabilities within 15 days after publication of this synopsis. Interested organizations may submit their capabilities and qualifications to perform the effort in writing to Odessia Becks via e-mail at Odessia.H.Becks@nasa.gov not later than 4:30 p.m. local time on June 4, 2018. Such capabilities/qualifications will be evaluated solely for the purpose of determining whether or not to conduct this procurement on a competitive basis. A determination by the Government not to compete this proposed effort on a full and open competition basis, based upon responses to this notice, is solely within the discretion of the government. All responsible sources may submit an offer which shall be considered by the agency. Oral communications are not acceptable in response to this notice. The Government does not intend to acquire a commercial item using FAR Part 12. NASA Clause 1852.215-84, Ombudsman, is applicable. The Center Ombudsman for this acquisition can be found at http://prod.nais.nasa.gov/pub/pub_library/Omb.html. Point of Contact Name: Odessia Becks Title: Contract Specialist Phone: 301-286-8386
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Odessia Becks
Documents
No documents available.
Lifecycle
No additional notices in this lifecycle.
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
NON-COMPETITIVE COMBINED SYNOPSIS / SOLICITATION STREAMLINED SOLICITATION FOR COMMERCIAL ITEMS Solicitation Number: HHS-NIH-NIDA-SSSA-CSS-2018-1 Title: Development of White Matter Atlases for the Baltimore Longitudinal Study of Aging (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is HHS-NIH-NIDA-SSSA-CSS-2018-1 and the solicitation is issued as a request for quote. (iii) This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures; FAR Subpart 13.5-Simplified Procedures for Certain Commercial Items; and FAR Part 12-Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Station Support Contracts and Simplified Acquisitions Branch (SS/SA) on behalf of the National Institute of Neurological Disorders and Stroke (NINDS) intends to negotiate and award a purchase order without providing for full and open competition (Including brand-name) to The Vanderbilt University, 211 Kirkland Hall, Nashville, TN 37240-0001. This acquisition is conducted as non-competitive for a commercial item or service and is conducted under the authority of the FAR Subpart 13.5-Simplified Procedures for Certain Commercial Items and 13.501 Special documentation requirements and the authority of 41 U.S.C. 1901. Pursuant to FAR Subpart 13.501 (a) (1) (iii) the justification (excluding brand name) will be made available within 14 days after contract award or in the case of unusual and compelling urgency within 30 days after contract award. Pursuant to FAR Subpart 13.501 (a) (1) (iv) the rationale for the brand name justification is for continuity of research. The proposed contract principal investigator (Landman) has been the primary investigator charged with processing and analyzing the diffusion tensor (DTI) imaging data within the BLSA since 2010. As of June 2016, 2023 DTI MRI sessions (on 1042 subjects) have been pre-processed, analyzed with tensor models , and returned to the BLSA for analysis. The proposed Contractor is uniquely qualiied to develop and evaluate the new labeled atlases for application to BLSA MR images. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2005-95-1, dated January 19, 2017. (iv) The associated NAICS code 541711 - Research and Development in Biotechnology11 (except Nanobiotechnology) with a Size Standard of 1,00011 Employees. This requirement is single-sole sourced. (v) The contractor will provide manually labeled data to enable generalization of its structural imaging technologies to diffusion tensor imaging by manually labeling the brain white matter of representative subjects. (vi) Period of Performance: One year from data of award. (vii) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. (viii) The provision at FAR clause 52.212-2, Evaluation - Commercial Items, applies to this acquisition. (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. (b) Options. The Government will evaluate offers for award purposes by adding the total price for all options to the total price for the basic requirement. The Government may determine that an offer is unacceptable if the option prices are significantly unbalanced. Evaluation of options shall not obligate the Government to exercise the option(s). (c) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (ix) The Offerors to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items, with its offer. (x) The FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. (xi) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition. FAR clauses at 52.209-10, 52.233-3, and 52.233-4, Prohibition on Contracting with Inverted domestic Corporations, Protest After Award, and Applicable Law for Breach of Contract Claim, respectively, appy to this acquisition. (xii) There are no additional contract requirement(s) or tems and conditions applicable to this acquisition. (xiii) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xiv) Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. Respondents that believe that they are manufacturers or authorized resellers of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order. Responses to this solicitation must include clear and convincing evidence of the offeror's capability of fulfilling the requirement as it relates to the technical evaluation criteria. The price proposal must include the labor categories, an estimate of the number of hours required for each labor category, fully loaded fixed hourly rate or each labor category, breakdown and rationale for other direct costs or materials, and the total amount. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." All responses must be received by Friday, Occtober 6, 2017 at 12PM, Eastern Standard Time, and reference number HHS-NIH-NIDA-SSSA-CSS-2018-1. Responses may be submitted electronically to Danielle R. Brown, Contract Specialist, at Danielle.brown2@nih.gov. Fax responses will not be accepted. (xv) Please contact Danielle R. Brown, Contract Specialist, at Danielle.brown2@nih.gov or (301) 594-1928 with any questions. | - | Combined Synopsis | Open |
This RPP is being issued by the Defense Health Agency Contracting Activity (DHACA), in support of the Defense Health Agency’s Portfolio Acquisition Executive (PAE) Medical Products (MP) Warfighter Protection (WPAC) & Acute Care Program Management Office (PMO) Care located in Frederick, Maryland at Fort Detrick. The Warfighter Protection and Acute Care Project Management Office (WPAC PMO) has a requirement for the development of a Barrier Combination product. The Barrier Combination product is defined as being composed of both a physical barrier to protect a wound and an antibacterial and/or antifungal activity released from the barrier to prevent the spread of organisms and avoid systemic infections. This RPP will result in one award to develop the Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination (BC) prototype product. The final product MUST be a combination wound treatment that includes a barrier component that is either infused or impregnated with antimicrobial and/or antifungal properties and have U.S. Food Drug Administration (FDA) approval (or clearance). The award, as a result of this RPP, will be awarded under the authority of prototype Other Transaction Authority (pOTA) 10 U.S.C. 4022. NOTE: Another amendment will be posted which will include Offeror questions and Government responses. (Amendment 0003 only extends the proposal due date). Amendment 0001 – removed alternate point of contact information under “Contract Information” on SAM.gov Amendment 0002 – revised proposal due date from: 12:00pm eastern, Friday, 23 Oct 2026 to: 12:00pm eastern Friday, 06 Nov 2026 Amendment 0003 – revised proposal due date from: 12:00pm eastern Friday, 06 Nov 2026 to: 12:00pm eastern Friday, 20 Nov 2026 Amendment 0004 – Incorporates Attachment J - Offeror questions & Government responses, Updates RPP, Attachment A – SOO, Attachment E- Draft Agreement Terms & Conditions, Attachment H – SOW Template, and adds Attachment K – CMMC Level I Self-Assessment Instructions. | - | Solicitation | 11/20/2026 |
The United States Army Contracting Command-Detroit Arsenal on behalf of Project Manager Solider Survivability (PM SSV) intends to solicit on a sole source basis under the statutory authority permitting Other than Full and Open Competition 10 United States Code 3204(b)(B)(ii), as implemented by Federal Acquisition Regulation 6.302-1(a)(2)(iii)(B), Services may be deemed to be available only from the original source in the case of follow-on contract for the continued provision of highly specialized services when it is likely that award to any other source would result in unacceptable delays in fulfilling the agency’s requirements, to DCS Corporation, 6909 Metro Park Drive Suite 500, Alexandria Virginia 22310 for the procurement of four (4) months of Systems Engineering and Technical Assistance (SETA) Support Services. The procurement of the services will be executed via a modification to an existing award. This notice is not a request for proposals or quotations. Requests for copies of a solicitation in response to this notice will not be honored or acknowledged. A determination by the Government not to compete this proposed action based upon responses to this notice is solely within the discretion of the Government. Interested parties may identify their capabilities by responding to this requirement, no later than 3:30 pm EST, 14 August 2026. All information submitted should support the offeror's capability to provide the services required, and shall be furnished at no cost or obligation to the Government. Responses must be in writing and must provide clear and concise documentation indicating an offeror's bona fide capability to provide these services. Verbal responses are not acceptable and will not be considered. Responses shall be submitted via email to lieselotte.h.pattee.civ@army.mil and theresa.s.quick.civ@army.mil. | - | Special Notice | 11/27/2026 |
Synopsis: This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources to perform a potential requirement; (2) whether they are small businesses; 8(a) small businesses, service-disabled veteran-owned small businesses; veteran-owned small businesses; women-owned small businesses; HUBZone small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification system (NAICS) code for the potential acquisition. Your responses to the information requested will assist the government in determining the appropriate acquisition method, including whether a small business set aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. The requirement is assigned a code of 541715 in the North American Industry Classification System (NAICS), and the small business size standard for such requirements is 1,000 employees or less. This notice is issued for market research purposes to assess potential small business sources, industry practices, and the availability of commercial services. The Government has not made a final determination regarding acquisition strategy, contract type, commerciality, or small business set-aside status. Respondents should identify whether they can perform the requirement as a prime contractor, including through existing teaming arrangements or qualified subcontractors, and distinguish their own capabilities from those of proposed team members. Background: The National Institute on Minority Health and Health Disparities (NIMHD) conducts and supports research and training programs to advance knowledge and understanding of health disparities, identify mechanisms to improve minority health and reduce health disparities, and develop effective interventions in community and clinical settings. NIMHD is the lead organization at the National Institutes of Health (NIH) for planning, reviewing, coordinating, and evaluating minority health and health disparities research activities. NIMHD also promotes workforce development, supports research capacity at less-resourced institutions that train students in research careers, serves populations experiencing health disparities, supports participation in clinical research, and promotes information dissemination through regular communications, public education outreach, and scientific presentations. The President’s Executive Order (EO) 14212 Establishing the President’s Make America Healthy Again Commission aims to improve the health of Americans. As described in the EO, escalating burden of chronic diseases poses significant challenges in the United States. These conditions contribute to rising health costs, reduced workforce productivity, and stagnant life expectancies across the country, both in adults and children. NIH defines a health disparity as a measurable difference in health that exists between specific population groups. This is a rigorously derived and data-driven determination operationalized by quantifiable metrics, rather than a statement of attribution. It is a scientific starting point that identifies where health outcomes diverge, not a predetermined conclusion about why. Scientific investigations to identify or understand the root causes are separate and distinct scientific questions, which are necessarily multifaceted and complex. NIH funded research is interested in those health disparities that are modifiable or actionable to improve the health of all population groups. Health disparities may be observed in the risks, prevalence, or problems resulting from specific behaviors, as well as the incidence, prevalence, and mortality from conditions, diseases, and/or disorders. To fulfill the NIH mission of seeking fundamental knowledge about the nature and behaviors of individuals as living systems, and the statutory purpose of NIMHD, to conduct research to understand and reduce health disparities, NIMHD Division of Intramural Research (DIR) conducts population health research to understand how health outcomes vary across populations, identify multilevel modifiable factors that drive these disparities, and develop, test, and evaluate clinical and population-based interventions to reduce these disparities. NIMHD DIR requires contractor assistance to provide R&D social and behavioral sciences research services to support NIMHD DIR in conducting population health and clinical research to understand and reduce health disparities in the United States. The Government anticipates that individual task orders may involve differing research designs, study populations, sites, durations, and levels of complexity. Interested firms should explain their ability to mobilize qualified personnel and research resources for multiple concurrent studies as requirements arise. NIMHD is seeking small businesses capable of designing, conducting and overseeing the clinical, scientific, and technical aspects of investigations into health disparities across populations, to identify modifiable risk and protective factors associated with these disparities, and develop and test interventions to reduce these disparities. Study designs to be used may include, but are not limited to: Population-based cross-sectional surveys; Epidemiological studies (e.g., longitudinal cohort study, case-control studies); Clinical trials; Community-based intervention studies; Simulation modeling; and Qualitative research methods (e.g., direct observations, in-depth interviews, focus groups discussions). Independently and not as an agent of the Government, the Contractor shall furnish all necessary services, qualified personnel, material, equipment, and facilities not otherwise provided by the Government to successfully perform the requirements stated below. Specifically, the Contractor shall, as required by individual task orders, perform the following technical requirements summarized below that also are included in the attached Draft Statement of Work (SOW), including but not limited to: Provide personnel, facilities, and other services necessary to maintain and coordinate multiple health disparities research studies funded through task orders under this Indefinite Delivery, Indefinite Quantity (IDIQ) contract. Provide overall project management and coordination of activities performed under individual task orders, including development and maintenance of project plans, schedules, milestones, coordination of participating research sites and subcontractors, monitoring of performance, identification and resolution of project risks and issues, and preparation of progress reports as specified in the applicable task order. Conduct research studies through qualified organizations, as specified in individual task orders, and receiving consent from the Contracting Officer’s Representative (COR) and Contracting Officer (CO). This includes (but is not limited to) implementation of protocols; population health and clinical research site monitoring; regulatory compliance assurance; and analyses of data from clinical, laboratory, population and epidemiologic studies. Provide and manage participating population health research and clinical trial sites, investigators, laboratories, and other research resources necessary to conduct studies, directly or through qualified subcontractors. The Contractor shall draft, negotiate, execute, administer, monitor, renew and/or modify as necessary, subject to subcontractor's satisfactory past performance, and with the consent of the CO, subcontracts with domestic population health studies, clinical research sites and laboratories, and provide support for these population health studies, clinical research site and laboratories. The Contractor shall assume responsibility for population health and clinical sites, including site readiness to start new research studies. This includes the establishment of new subcontract agreements for these sites (including laboratories), data management, and other operations and functions. As existing protocols close, the Contractor shall assume responsibility for any new protocols at these sites. Recruit and retain numbers of potential research subjects sufficient for the timely completion of all protocols. Provide United States based investigators in the United States with expertise in the population health and clinical care, to conduct protocols specified through individual task orders. Provide professional and technical staff adequate to provide scientific and administrative coordination of multiple population health and clinical health disparities research studies. These staff shall include, but are not limited to, qualified medical, nursing, and neuropsychologic staff, study coordinators, personnel for participant identification, recruitment, study conduct, and retention, pharmacists, and laboratory technicians. Ensure sites have access to populations of interest, laboratory facilities with the capability to perform clinical research specified in task orders. Identify and engage community organizations, community leaders, health care providers, and other relevant stakeholders; establish and support community advisory boards, community coalitions, or other partnerships; conduct community needs and readiness assessments; and facilitate community participation in research planning, implementation, and dissemination of findings. Develop and implement quantitative and qualitative data collection methods, including surveys, interviews, focus groups, direct observations, and other methods appropriate to the research protocol. The Contractor shall manage, analyze, and report data collected through these methods, as required by individual task orders. Provide facilities and equipment adequate to conduct population health, inpatient and outpatient clinical research studies. Equipment purchases must be approved by the COR and CO. Ensure that sites have (through lease or direct provision, if required) electronic information systems compliant with the Federal Information Security Modernization Act (FISMA), necessary specialized equipment (including hardware and software) for sites to electronically communicate with the Contractor, subcontractors, and NIMHD DIR as required, for processing and storage of biospecimens (e.g., ultralow temperature freezer, specialized shipping materials and training for shipment of biohazardous materials and dangerous goods, and for receipt, storage, monitoring, and dispensing of investigational drugs). Obtain access for research protocol review and approval (or exemption) to a standing Institutional Review Board (IRB) and ensure that each institution conducting population health and clinical research studies has a current, approved Federal-Wide Assurance Number on file with the Office for Human Research Protections (OHRP). Ensure that all the staff at each site participating in the design or conduct of population health and clinical research involving human subjects, complete and maintain education on the human research protections. Ensure that when appropriate, population health and clinical research sites have a community advisory board (CAB) constituted with members of the local community that can provide community perspective and advice for science in the community where the population health and clinical research is located and that provides community input. The Contractor shall provide services to ensure regulatory compliance for research activities including subcontracted sites' performance. More specifically: Ensure site access to a communications system in compliance with U.S. Food and Drug Administration (FDA) requirements for the submission of Adverse Experience Reports (AERs) by Subcontractors to the Contractor for transmission as required to the COR as required. Monitor the accuracy of adverse experience reporting through regular summary reports for submission to the COR. Draft safety reports as required by the FDA for selected studies for COR Submission. Develop, implement, and monitor plans for acquisition, distribution, dispensing, handling, administration, and accountability of study interventions (pharmaceutical and non-pharmaceutical), in compliance with applicable Federal, state, and local regulations. Provide site monitoring for quality assurance of research conducted at all clinical and laboratory sites, as designated by the COR. Monitoring schedules shall be approved by and results reported to the COR with a copy to the CO and shall include assurance of compliance with FDA record keeping and reporting requirements (21 CFR 50 and 56; 21 CFR 312.50, Subpart D), accuracy and completeness of case report forms, source documentation, and other research records, and periodic record auditing and documentation by the staff of the subcontracted centers. Each site shall be visited a minimum of 2-3 times annually. Provide staff with laboratory expertise and assist in monitoring clinical trials site laboratory quality with the COR and NIMHD Quality Assurance (QA) programs. Meet with the NIMHD program and contracting staff to review annual site performance and monitoring reports for participating population health and clinical research sites. The Contractor shall provide population health, clinical and statistical analysis and reports. More specifically: Provide scientific, technical, and administrative support for the development, implementation, and analysis of the specified research, including considerations of experimental design, sample size calculation, and interim and final primary and secondary analyses specified by study protocols, as requested by the COR. Establish data elements to be recorded by the protocol research records, as requested by the COR and in conjunction with the protocol development team for each specific research project. Develop study forms for standardized collection of data items. Develop documentation and coding for computerization of data for retrieval, analysis, and reporting. Provide for timely and accurate data collection and submission, data entry, data quality assurance, retrieval of source documentation, and generation of data and safety monitoring reports. Provide training for staff of population health, clinical and laboratory sites in data management procedures. Provide data input, editing, electronic data storage, database management, data retrieval, and statistical analysis using well-documented database management and statistical computer software programs. Develop methodology, perform analyses, and provide results from meta-analyses of selected data sets derived from population health and clinical research studies that focus on health disparities. Provide data analysis and results. More specifically: Perform statistical analyses of study data to test study hypotheses and evaluate potential confounding variables and/or covariates, as requested by the COR. Data analytic techniques needed include approaches to analyzing multiple measurements of biologic variables over time within participants and between participant groups, with consideration for normal changes in these variables with demographics. Provide for biweekly to monthly communication, as needed, of analytic progress and results through routine meetings (the majority to be virtually) with COR or designees and periodic generation of reports. The Project Manager shall attend all meetings. The Epidemiologist, Statistician, and Senior Systems Analyst shall attend these meetings on an as needed basis dependent upon the PI’s request. Provide programming and statistical support adequate for the timely generation of additional analyses requested by the COR. Provide electronic data transmission between the Contractor, population health, clinical and laboratory sites, and NIMHD DIR using currently specified communications software and equipment. Provide for electronic mail transmission between the Contractor, population health, clinical and laboratory sites, and NIMHD DIR using commercially available communications software and equipment. Provide protocol development services and assistance. The Contractor shall provide services for the implementation and monitoring of multiple population health and clinical research studies. More specifically: Develop, initiate and coordinate implementation and oversight of protocols at all participating population health, clinical and laboratory sites designed by the COR and approved by the CO. Ensure compliance by sites with all requirements for protocol implementation, including IRB review and approval prior to protocol initiation, participant consent, and confidentiality requirements, and Federal bioresearch regulations and requirements for security and confidentiality of research records, and that each relevant population health and clinical research site staff member completes and maintains human research protection and Good Clinical Practice training, when appropriate. Draft, negotiate, execute, administer, monitor, renew and/or modify as necessary with approval by CO a site-specific, protocol-specific budget for each protocol to be conducted by population health, clinical and laboratory sites, based on the anticipated number of participants to be enrolled. Provide training for staff of clinical and laboratory centers in procedures for implementation and conduct of specific protocols. Retraining may be required to be performed as necessary. Provide training in and ensure the fulfillment and maintenance of standards for Good Clinical Practices (GCP) and Good Clinical Laboratory Practices (GCLP) across population health and clinical research sites and staff, whenever appropriate. Ensure timely development and execution of material transfer agreements (MTAs) and data transfer agreements (DTAs) between the sponsor(s) and population health and clinical research sites. The Contractor shall provide services for the development and review of research activities. More specifically: For specific new protocol topics identified by the COR, identify a protocol development team consisting of Contractor staff, NIH staff, subcontractors, and/or consultants. Provide support for the planning and conduct of protocol development team meetings. Submit at the initial meeting a protocol development plan for COR review and approval, addressing regulatory issues, data collection forms development, drug distribution plan, protocol timeline, and participating sites. Develop a protocol document including background, objectives and endpoints, design, patient numbers, source, management, and selection, study agents or other interventions, clinical and laboratory monitoring, laboratory services, toxicity management, adverse experience reporting, evaluation of response, statistical considerations, data collection and monitoring, human subjects’ considerations, biohazard containment, and data and safety reviews. Review, edit, and rewrite draft protocols based on COR’s review. Prepare and maintain the necessary documentation for application submissions in compliance with FDA requirements. Upon completion of a final protocol, renegotiate subcontractor budgets with the approval of the CO and implement the new protocol at participating sites. For ongoing protocols, provide, at the request of the COR, support for the planning and conduct of meetings of protocol committees and subcommittees, data and safety monitoring boards, and investigators. Provide administrative, technical, and logistical support at the request of the COR and with approval of the CO as needed for interaction and collaboration of the Subcontractors with other institutes, agencies, and organizations conducting activities relevant to health disparities research. Support the identification, development, implementation, and evaluation of interventions to improve health outcomes and reduce health disparities, including assessment of feasibility, acceptability, effectiveness, and potential impact. Provide consultants with specialized expertise related to population health and clinical research especially related to health disparities, as requested by NIMHD DIR. Plan, organize, and coordinate meetings involving internal and outside experts. This meeting will be an important venue to discuss important and complex scientific issues related to research protocols and emerging research priorities. Provide support services for ongoing population health and clinical research studies, which include, but are not limited to, the following: site monitoring, subcontract management and invoicing, protocol management, oversight of data management and data analysis, study agent procurement, team meetings, regulatory compliance assurance, site activation and protocol registration, safety monitoring, committee management, data management services, oversight of central and site laboratories and pharmacies, protocol team support, FISMA compliance and IT security, laboratory equipment support, and training of site personnel, to support this effort. Provide Core infrastructure support for ongoing population health and clinical research at the sites, including but not limited to the following: maintenance of IRB/EC regulatory reporting, subject recruitment and follow-up, Community Advisory Board (CAB) support for meetings, protocol updates and reporting, attendance and participation in site monitoring visits, attendance at the annual network meeting, invoicing and other report preparation. Experience coordinating data from all aspects of ongoing protocols, studies, and trials. Experience in initiating and managing 3-6 studies each year. Experience initiating and managing studies of different sizes from approximately 100 participants up to approximately 10,000 participants. Experience working with populations experiencing health disparities, e.g., people in low socioeconomic conditions, living in rural underserved areas, and racial and/or ethnic populations who have documented health disparities based on diseases and conditions. Experience initiating and managing studies with a length in time from a few months for cross-sectional studies to a few years in clinical studies. Experience managing studies of varying complexities from simpler studies, which may be qualitative studies involving in-depth interviews with about 100 people; to more complex studies that involve a multi-site clinical trial with 1-2 years follow-up including biospecimen collection. Commercial Availability of Services – Based on preliminary market research, the Government anticipates that the contemplated research services may be noncommercial in nature. However, interested respondents are encouraged to identify comparable services available in the commercial marketplace. If so, describe which portions of the requirement could be met commercially and which would require customization, integration, or specialized development. Provide supporting information, including customary pricing practices and potential firm-fixed-price arrangements, if available. Industry Feedback on Draft SOW – Respondents are encouraged to provide comments or recommendations on the draft SOW, including opportunities to clarify requirements, improve performance outcomes, identify potential implementation challenges, or incorporate commercially available approaches. Identify any provisions that may unnecessarily limit small business participation and suggest practical alternatives. Any recommendations should identify the applicable SOW section when possible. Anticipated Award Date: The Government expects to award an Indefinite Delivery Indefinite Quantity (IDIQ) contract approximately in September 2027. Disclaimer and Important Notes: This notice does not obligate the government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this Notice. This notice is for information purposes only. CONFIDENTIALITY: No proprietary, classified, confidential, or sensitive information should be included in your response. The government reserves the right to use any nonproprietary technical information in any resultant solicitation(s). Responses and Capability Statements: Interested Small Businesses that believe they possess the capabilities necessary to undertake this project should submit an electronic copy of their capability statement addressing the areas listed above to the attention of Edwin Osorio, Contract Specialist (E-mail: edwin.osorio@nih.gov) and Lisa Schaupp, Contracting Officer (E-mail: lisa.schaupp@nih.gov). Please state clearly in the subject line of the email that it is in response to the Sources Sought notice no.75N94027R00005. Please limit responses to 20 pages or less, exclusive of resumes. Electronic capability statements should be received by the Contracting Officer and Contract Specialist by 4:30 PM Eastern time on November 25, 2026. Respondents must submit their capability statement via electronic submission only. Capability statements must identify the 1) organization name, address, point of contact, contact phone number, and email address; 2) Small Business status of the organization, NAICS code along with SAM.gov Unique Entity Identifier (UEI) and CAGE code, if assigned, size and type of business (e.g., 8(a), HUBZone, etc.). No phone calls will be accepted. The designated NAICS code for this effort is 541715 and the size standard is 1,000 employees or less. Respondents may provide brief SOW comments and commercial availability information within the existing 20-page response limit. The Government may use the information received to refine the draft SOW and acquisition strategy; participation does not preclude responding to any future solicitation. | - | Market Research | 11/25/2026 |
Randomized Controlled Trial of a Novel Clinical Decision Support Tool for Individualized Exercise Recommendations in Breast Cancer Survivors. | - | Pre-Solicitation | 11/25/2026 |
Additional Details
Solicitation Number
VOYAGER_PROJECT
Archive Date
Jan 1, 2022